Every Form 4 that Silexion Therapeutics Corp (SLXN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SLXN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLXN filings page.
Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.
The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.
Horenshtein Hadar Mirit reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that its CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 7,500 fully vested restricted share units that were immediately settled into ordinary shares, at a stated price of $0.00 per share, for service as an officer. Following this award, the reporting person directly holds 12,515 ordinary shares. A prior 1-for-10 reverse share split on May 28, 2026 adjusted earlier beneficial holdings from 50,146 ordinary shares at $0.0135 par value to 5,015 ordinary shares at $0.135 par value before this grant.
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.
Silexion Therapeutics Corp CSO and CDO Shirvan Mitchell reported an open-market sale of 22,818 Ordinary Shares on March 26, 2026 at $1.36 per share. According to the footnotes, this was a sale-to-cover transaction to pay tax liabilities from a fully vested restricted share unit grant received on February 20, 2026.
After the sale, Mitchell directly held 27,889 Ordinary Shares. He also held a stock option over 478 Ordinary Shares with an exercise price of $907.71 per share and an expiration date of June 7, 2032, adjusted to reflect prior reverse share splits.
Noy Shlomo reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund (GIBF), an entity associated with director Noy Shlomo, was granted equity awards in connection with director services provided by GIBF’s CEO and Managing Partner, Avner Lushi. GIBF received fully vested restricted share units that were immediately settled into 9,091 ordinary shares, at a price of $0.00 per share. GIBF was also granted 10,685 stock options to purchase ordinary shares, with these options vesting in full on the one‑year anniversary of the board’s approval date and expiring on the ten‑year anniversary of that approval. The filing notes that Shlomo has shared voting and investment authority through his role as Chief Medical Officer of GIBF and disclaims beneficial ownership beyond any indirect pecuniary interest, and one line item is included only to show existing holdings with no new transaction.
Silexion Therapeutics Corp director Alon Ruth received new equity awards in the form of both shares and options. On February 20, 2026, Ruth was granted 9,091 Ordinary Shares at a price of $0.0000 per share, issued through fully vested restricted share units that were immediately settled into ordinary shares for his board service.
On the same date, he also received a grant of stock options covering 10,685 Ordinary Shares at an exercise price of $0.0000 per share, reflecting compensation for his role as a director. According to the filing, these options vest in full on the one-year anniversary of the grant approval date and expire on the ten-year anniversary of that approval date, providing a long-dated incentive tied to his continued board service. An additional row in the filing simply updates existing option holdings and does not reflect a new transaction.
Shirvan Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp chief scientific and development officer Shirvan Mitchell received a grant of 49,726 fully vested restricted share units that were immediately settled into ordinary shares at no cost, for his services as an officer and approved by the board. Following this award, his direct holdings total 50,707 ordinary shares, and he also directly holds stock options covering 478 ordinary shares, which are reported here for informational purposes only. The share and option amounts reflect prior 1-for-9 and 1-for-15 reverse share splits effective in late 2024 and mid‑2025.
Silexion Therapeutics Corp reported that CFO and Secretary Hadar Mirit Horenshtein acquired 49,726 Ordinary Shares on account of a fully vested restricted share unit grant. The RSUs were immediately settled into ordinary shares as compensation for service as an officer, approved by the board of directors.
Following this grant, Horenshtein directly owns 50,146 Ordinary Shares of Silexion Therapeutics Corp.
Hadar Ilan reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp Chairman and CEO Hadar Ilan received a grant of 64,350 fully vested restricted share units that were immediately settled into ordinary shares at a price of $0.0000 per share, as compensation for officer services and approved by the board. Following this award, Ilan directly holds 65,471 ordinary shares. The filing also lists 956 stock options to buy ordinary shares for informational purposes only, with no new option transaction reported.
Abramov Dror Yosef reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Abramov Dror Yosef reported equity awards on February 20, 2026. He received 9,091 ordinary shares through a grant of fully vested restricted share units that were immediately settled into shares for his director services, as approved by the board.
He was also granted 10,685 stock options to buy ordinary shares, with these options vesting in full on the one-year anniversary of the board’s approval date and expiring ten years after that approval. Following these awards, he held 10,180 ordinary shares directly, and a separate line shows 935 stock options as an existing holding included for informational purposes.
Peled Amnon reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Amnon Peled received equity awards from the company. On February 20, 2026, he was granted 7,576 ordinary shares at no cost through fully vested restricted share units issued for his director services.
On the same date, he was also granted stock options for 8,904 ordinary shares, with the options vesting in full one year after the board’s approval date and expiring ten years after that approval. An additional option holding of 780 shares was reported for informational purposes only, with no transactions effected in that line.
Lushi Avner reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund, an entity associated with director Lushi Avner, received equity awards for director services. The fund was granted 9,091 ordinary shares via fully vested RSUs and 10,685 stock options. These options vest in full on the one-year anniversary of board approval and expire ten years after that approval date. An additional 1,872 stock options are reported as existing holdings with no new transaction.
Silexion Therapeutics Corp insider entities led by Ilan Levin and Moringa Sponsor, LP reported several share and warrant changes. On August 7, 2025, Moringa Sponsor, LP made a pro rata distribution of 5,550 ordinary shares and 935 warrants to its limited partners for no consideration, leaving 6,970 ordinary shares and 372 warrants indirectly held through that entity. On September 15, 2025, Moringa Sponsor, LP received 450,000 ordinary shares upon conversion of $1,800,000 of principal under a convertible promissory note at $4.00 per share, an issuance approved by the board.
The reporting persons state they dispute the validity of this 450,000-share issuance and do not concede beneficial ownership of those shares. The filing also notes 1-for-9 and 1-for-15 reverse share splits that reduced reported share and warrant counts, and includes 1,482 ordinary shares held via Greenstar, L.P. for informational purposes.